New York, USA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ulcerative Colitis Market to Grow Positively by 2032, Predicts DelveInsight | Key Companies - Arena, Pfizer, Abivax, InDex, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast
With time ulcerative colitis market landscape is evolving and the treatment goals continue to shift hence the dynamics of the ulcerative colitis therapeutic market are anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with ulcerative colitis.
DelveInsight’s Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted ulcerative colitis market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Ulcerative Colitis Market Report
- As per DelveInsight’s analysis, the ulcerative colitis market size was found to be USD 8 billion in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total diagnosed prevalent cases of ulcerative colitis in the 7MM comprised approximately 3 million in 2022 and are projected to increase during the forecasted period.
- Leading ulcerative colitis companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others are developing novel ulcerative colitis drugs that can be available in the ulcerative colitis market in the coming years.
- Some of the key therapies for ulcerative colitis treatment include Etrasimod (APD334), ABX464 (Obefazimod), SHR0302 (Ivarmacitinib), Cobitolimod, SKYRIZI (risankizumab), TREMFYA (Guselkumab), BT-11 (Omilancor), PRA023, Remestemcel-L, PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib), and others.
- In the United States, anti-TNFaagents (adalimumab, infliximab, golimumab), interleukin antagonists (ustekinumab, mirikizumab), anti-integrin agents (vedolizumab), S1P receptor modulator (ozanimod), and JAK inhibitors (tofacitinib, upadacitinib), are approved for the treatment of moderate to severe ulcerative colitis patients.
Discover which therapies are expected to grab the major ulcerative colitis market share @ Ulcerative Colitis Market Report
Ulcerative Colitis Overview
Ulcerative colitis stands as one of the two primary forms of chronic inflammatory conditions in the gastrointestinal tract, categorized under the umbrella term “inflammatory bowel disease,” with the other being Crohn's disease. It is an idiopathic, persistent inflammation of the colon's inner lining and typically presents with symptoms like diarrhea, abdominal pain, and bloody stools. The severity of ulcerative colitis symptoms can vary widely, ranging from mild discomfort to extremely debilitating. Additional common manifestations include abdominal cramps, fatigue, a general feeling of unwellness, diminished appetite, weight loss, and anemia. Beyond the gastrointestinal tract, ulcerative colitis can also trigger complications in other areas of the body, such as the joints, eyes, or skin. The diagnosis of Ulcerative Colitis relies on a combination of factors including medical history, clinical assessment, serological data, and various observations. Patients with Ulcerative Colitis can be distinguished by assessing factors such as disease extent, severity, age of onset, extraintestinal symptoms, and genetic markers. Rather than relying on a single definitive test, the diagnostic process involves a comprehensive evaluation combining symptoms with endoscopic examinations, biopsies, stool analyses, and a range of imaging modalities (including plain radiographs, fluoroscopy, CT scans, and MRI scans).
Ulcerative Colitis Epidemiology Segmentation
The ulcerative colitis epidemiology section provides insights into the historical and current ulcerative colitis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The ulcerative colitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Ulcerative Colitis Prevalent Cases
- Total Ulcerative Colitis Diagnosed Cases
- Ulcerative Colitis Severity-specific Cases
- Ulcerative Colitis Age-specific Cases
Download the report to understand which factors are driving ulcerative colitis epidemiology trends @ Ulcerative Colitis Epidemiological Insights
Ulcerative Colitis Treatment Market
The treatment objectives for ulcerative colitis have transitioned from merely alleviating symptoms and achieving clinical remission to more stringent benchmarks. These now encompass maintaining steroid-free remission, reducing the risk of hospitalization and surgery, promoting mucosal healing, enhancing quality of life, and preventing long-term disability. Treatment plans are highly individualized to cater to each patient’s unique requirements, tailored to the severity of their condition and specific symptoms. Managing ulcerative colitis is a personalized endeavor, tailored to each patient’s unique needs based on the disease’s severity and symptomatology. This comprehensive strategy encompasses a multifaceted approach, incorporating medication, dietary modifications, and, when necessary, surgical interventions to repair or remove affected portions of the gastrointestinal tract. Surgical options like total proctocolectomy, restorative proctocolectomy, and elective colorectal cancer surgery are considered for patients who do not respond to medical therapies and experience a substantial decline in their quality of life.
Various medications are employed in the treatment of ulcerative colitis. These include aminosalicylates, which help reduce inflammation in the intestinal lining, corticosteroids that block allergic and inflammatory triggers, immunosuppressants, Janus kinase inhibitors, and other options. Approved therapies for moderate-to-severe ulcerative colitis encompass REMICADE, STELARA, XELJANZ, and RINVOQ. Anticipate growth in the ulcerative colitis market in the coming years due to evolving treatment options with multiple new entrants.
Learn more about the FDA-approved drugs for ulcerative colitis @ Drugs for Ulcerative Colitis Treatment
Key Ulcerative Colitis Therapies and Companies
- Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
- ABX464 (Obefazimod): Abivax
- SHR0302 (Ivarmacitinib): Reistone Biopharma
- Cobitolimod: InDex Pharmaceuticals
- SKYRIZI (risankizumab): AbbVie/Boehringer Ingelheim
- TREMFYA (Guselkumab): Janssen Pharmaceuticals
- BT-11 (Omilancor): Landos Biopharma/NImmune
- PRA023: Merck
- Remestemcel-L: Mesoblast
- PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib): Pfizer
To know more about ulcerative colitis clinical trials, visit @ Ulcerative Colitis Treatment Drugs
Ulcerative Colitis Market Dynamics
The ulcerative colitis market dynamics are anticipated to change in the coming years. Various medications are employed in the treatment of ulcerative colitis. These include aminosalicylates, which help reduce inflammation in the intestinal lining, corticosteroids that block allergic and inflammatory triggers, immunosuppressants, Janus kinase inhibitors, and other options. Approved therapies for moderate-to-severe ulcerative colitis encompass REMICADE, STELARA, XELJANZ, and RINVOQ. Anticipate growth in the ulcerative colitis market in the coming years due to evolving treatment options with multiple new entrants.
However, several factors may impede the growth of the ulcerative colitis market. Patients with ulcerative colitis face substantial challenges due to the absence of curative treatment options. While Anti-TNF agents are considered highly effective, their use is associated with the development of immunogenicity and significant adverse effects. Ulcerative colitis often presents with severe complications and comorbidities such as extra-intestinal manifestations (EIMs), toxic megacolon, and colitis-associated colorectal cancer (CACC), necessitating additional medications and treatments that complicate ulcerative colitis management and drive up costs. The ulcerative colitis market is experiencing heightened competition due to the emergence of numerous new therapies, resulting in ulcerative colitis market saturation.
| Ulcerative Colitis Report Metrics | Details |
| Study Period | 2019–2032 |
| Ulcerative Colitis Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Ulcerative Colitis Market Size in 2022 | USD 8 Billion |
| Key Ulcerative Colitis Companies | Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others |
| Key Ulcerative Colitis Therapies | Etrasimod (APD334), ABX464 (Obefazimod), SHR0302 (Ivarmacitinib), Cobitolimod, SKYRIZI (risankizumab), TREMFYA (Guselkumab), BT-11 (Omilancor), PRA023, Remestemcel-L, PF-06651600 (ritlecitinib) and PF-06700841 (brepocitinib), and others |
Scope of the Ulcerative Colitis Market Report
- Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
- Ulcerative Colitis Market Dynamics: Attribute Analysis of Emerging Ulcerative Colitis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Ulcerative Colitis Market Access and Reimbursement
Discover more about ulcerative colitis drugs in development @ Ulcerative Colitis Clinical Trials
Table of Contents
| 1. | Ulcerative Colitis Market Key Insights |
| 2. | Ulcerative Colitis Market Report Introduction |
| 3. | Ulcerative Colitis Market Overview at a Glance |
| 4. | Ulcerative Colitis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Ulcerative Colitis Treatment and Management |
| 7. | Ulcerative Colitis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Ulcerative Colitis Marketed Drugs |
| 10. | Ulcerative Colitis Emerging Drugs |
| 11. | Seven Major Ulcerative Colitis Market Analysis |
| 12. | Ulcerative Colitis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Ulcerative Colitis Epidemiology Forecast
Ulcerative Colitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted ulcerative colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ulcerative Colitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ulcerative colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion Therapeutics, Palatin Technologies, Theravance Biopharma, VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio, Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb, Janssen Research & Development, GlaxoSmithKline, Assembly Biosciences, NuBiyota, Tarus Therapeutics, Servatus, Athos Therapeutics, Aclaris Therapeutics, Exeliom Biosciences SAS, Voronoi Group, Ventria Bioscience, TheraSource LLC, Synlogic Inc, Synedgen, Surrozen Inc, StemRIM Inc, Shaperon Inc, Sareum Holdings, Saniona, RhemaStem, Regentys, Progenity, Pharmaxis, Pharmabiome, PanTheryx, Oncodesign, Nyrada, Microbiotica, MAKScientific, KoBioLabs, Istesso, Intract Pharma, Innovimmune Biotherapeutics, Impetis Biosciences, Finch Therapeutics Group, Vivreon Biosciences, NuMedii, Intact Therapeutics, Giiant Pharma, among others.
Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Amgen, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., among others.
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Pipeline
Irritable Bowel Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
